Samsara Vision, which makes medical implants for retinal diseases including AMD, postponed its IPO on Friday. It had filed to raise $25 million by offering 4.2 million shares at a price range of $5 to $7.
Samsara Vision's current product line consists of its first-generation implantable miniature telescope (IMT), known as WA IMT; its Smaller-Incision, New Generation (SING) IMT; and its Tsert delivery system. WA IMT was approved by the FDA in 2010 and received a CE Mark in 2005. SING IMT received a CE Mark in April 2020, and the company began commercializing its SING IMT in Europe in 2021. In addition, it is in the process of establishing the regulatory pathway into the US.
The Far Hills, NJ-based company was founded in 2015 and had planned to list on the Nasdaq under the symbol SMSA. ThinkEquity was set to be the sole bookrunner on the deal.
